129 filings
Page 2 of 7
DEFA14A
xrx ctp95fbiwj0
6 Feb 24
Additional proxy soliciting materials
4:30pm
DEFA14A
vq3r khzf6f
23 Jan 24
Additional proxy soliciting materials
5:25pm
DEFA14A
e8ns4 b6izo
23 Jan 24
Additional proxy soliciting materials
6:38am
8-K
urx4 7qqv9zdkocprn2
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
8-K
3ewas
9 Nov 23
Inhibrx Reports Third Quarter 2023 Financial Results
4:03pm
8-K
k1q7 5uxib4bw
2 Nov 23
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
9:16am
8-K
p2pysf p24
19 Sep 23
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
4:03pm
D
vo5ybmwx
31 Aug 23
$200.00 mm in equity / options / securities to be acquired, sold $200.00 mm, 5 investors
4:06pm
8-K
d0sn7t3 qye6mahgbs
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
8-K
bpexa6kq naivm
7 Aug 23
Inhibrx Reports Second Quarter 2023 Financial Results
4:05pm
8-K
fq6xcmfl
30 May 23
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
9:03am
8-K
7nwynxna0husf
25 May 23
Submission of Matters to a Vote of Security Holders
4:08pm
8-K
z07a6v2h4ituvnmxob
8 May 23
Inhibrx Reports First Quarter 2023 Financial Results
4:05pm
8-K
294v25p z3
26 Apr 23
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
9:01am
DEFA14A
brbq5 tn1
13 Apr 23
Additional proxy soliciting materials
4:06pm